MBX Biosciences (MBX) Accumulated Depreciation (2023 - 2026)

MBX Biosciences has disclosed Accumulated Depreciation across 4 years of filings, most recently posting $734000.0 for Q1 2026.

• Accumulated Depreciation for Q1 2026 came in at $734000.0, up 47.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $734000.0 (up 47.09% YoY), and the FY2025 annual result was $670000.0, up 58.77% from the prior year.
• Accumulated Depreciation came in at $734000.0 for Q1 2026 at MBX Biosciences, up from $670000.0 in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $734000.0 in Q1 2026 to a low of $178000.0 in Q4 2023.
• The 4-year median for Accumulated Depreciation is $529500.0 (2025), against an average of $504625.0.
• Across the five-year window, Accumulated Depreciation surged 137.08% in 2024 and surged 47.09% in 2026, its largest moves.
• MBX Biosciences' Accumulated Depreciation stood at $178000.0 in 2023, then soared by 137.08% to $422000.0 in 2024, then soared by 58.77% to $670000.0 in 2025, then gained by 9.55% to $734000.0 in 2026.
• The last three Accumulated Depreciation figures came in at $734000.0 (Q1 2026), $670000.0 (Q4 2025), and $610000.0 (Q3 2025), per Business Quant data.